ReMuS Registry / ReMuS, The Czech Republic Multiple Sclerosis Patient Registry / ReMuS, Registr pacientů s roztroušenou sklerózou

ReMuS data are collected prospectively at all 15 highly specialised MS centres in the Czech Republic during routine clinical practice. These are the only facilities authorised to prescribe disease-modifying therapies (DMTs), and all are contractually part of the ReMuS network. Data are entered by treating neurologists and nurses into iMed software, built on structured drop-down menus and multiple-choice selections with limited free text.

The core data set covers: MS diagnosis and disease course, neurological episodes and disability (EDSS), relapses, DMT episodes (drug, start/stop dates, dosage, reason for discontinuation), adverse events (condition, severity, outcome, seriousness, suspected drug relationship), CSF and laboratory tests, and socio-demographics. MedDRA coding is used for serious adverse events since July 2023; retrospective conversion of historical free-text SAE records is ongoing. The BMSD Common Data Model (CDM) serves as the core harmonised output format.

Twice a year (30 June and 31 December), centres export data to a centrally secured ReMuS repository. iMed includes built-in validation checks; additionally, ReMuS runs a systematic quality process twice a year with over 100 rules, sending query reports to centres for verification against medical documentation. A continuous benchmarking framework drives data quality improvement across centres (Drahota et al., Mult Scler J 2025;31(3):880–882).

Established in 2013 under the IMPULS Endowment Fund with the Neuroimmunology and Liquorology Section (NLS) of the Czech Neurological Society, registry operations were spun off in 2024 into the ReMuS Endowment Fund.